|
Market Cap | 384.10M | EPS (ttm) | -0.34 |
P/E | - | EPS this Y | -14.67% |
Forward P/E | - | EPS next Y | 5.72% |
PEG | - | EPS past 5Y | -16.20% |
P/S | 8.45 | EPS next 5Y | - |
P/B | 1.73 | EPS Q/Q | 12.16% |
Dividend | - | Sales Q/Q | 15.33% |
Insider Own | 7.85% | Inst Own | 70.09% |
Insider Trans | -1.37% | Inst Trans | 0.19% |
Short Float | 3.91% | Earnings | Aug 06/a |
Analyst Recom | 1.25 | Target Price | 8.56 |
Avg Volume | 384.56K | 52W Range | 2.45 - 5.55 |
|
|
|
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Erck Stanley C | Director | Oct 01 '24 | Option Exercise | 0.04 | 26,082 | 1,043 | 295,200 | Oct 02 05:03 PM | Erck Stanley C | Director | Oct 02 '24 | Option Exercise | 0.04 | 21,607 | 864 | 290,725 | Oct 02 05:03 PM | Erck Stanley C | Director | Oct 01 '24 | Sale | 3.78 | 26,082 | 98,590 | 269,118 | Oct 02 05:03 PM | Erck Stanley C | Director | Oct 02 '24 | Sale | 3.71 | 21,607 | 80,162 | 269,118 | Oct 02 05:03 PM | Johnston John Joseph | Director | Sep 26 '24 | Option Exercise | 2.93 | 3,000 | 8,778 | 144,950 | Sep 30 04:15 PM |
|
|
|
|
Market Cap | 5.47B | EPS (ttm) | 4.77 |
P/E | 19.05 | EPS this Y | 60.05% |
Forward P/E | 15.25 | EPS next Y | -2.77% |
PEG | 1.52 | EPS past 5Y | -4.69% |
P/S | 1.04 | EPS next 5Y | 12.50% |
P/B | 3.02 | EPS Q/Q | 191.57% |
Dividend | 1.32% | Sales Q/Q | 10.62% |
Insider Own | 1.04% | Inst Own | 98.95% |
Insider Trans | -0.19% | Inst Trans | 2.23% |
Short Float | 1.31% | Earnings | Aug 07/a |
Analyst Recom | 2.00 | Target Price | 114.00 |
Avg Volume | 393.81K | 52W Range | 72.39 - 93.97 |
|
|
|
MAXIMUS, Inc. engages in the operation of government health and human services programs, and the provision of technology solutions to government. It operates through the following segments: U.S. Services, U.S. Federal Services, and Outside the U.S. The U.S. Services segment offers business process services (BPS), appeals and assessments, and related consulting work for U.S. state and local government programs. The U.S. Federal Services segment delivers end-to-end solutions and includes appeals and assessment services, system and application development, IT modernization, and maintenance services. The Outside the U.S segment provides BPS for international governments and commercial clients. The company was founded by David V. Mastran in 1975 and is headquartered in McLean, VA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Link Michelle F. | Chief of Human Resources | Oct 01 '24 | Sale | 92.56 | 1,363 | 126,159 | 6,567 | Oct 02 05:02 PM | Link Michelle F. | Officer | Oct 01 '24 | Proposed Sale | 92.56 | 1,363 | 126,159 | | Oct 01 12:22 PM | Warren Michael J. | Director | Sep 03 '24 | Buy | 92.40 | 13 | 1,217 | 4,068 | Sep 10 02:53 PM | Warren Michael J. | Director | May 31 '24 | Buy | 84.97 | 14 | 1,213 | 4,055 | Sep 10 02:53 PM | Warren Michael J. | Director | Feb 29 '24 | Buy | 84.05 | 7 | 603 | 4,041 | Sep 10 02:53 PM |
|
|
|
|
Market Cap | 10.55M | EPS (ttm) | -0.14 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | -32.55% |
Dividend | - | Sales Q/Q | - |
Insider Own | 59.28% | Inst Own | 3.05% |
Insider Trans | -23.93% | Inst Trans | 1.35% |
Short Float | 2.74% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 13.14M | 52W Range | 0.09 - 8.75 |
|
|
|
Conduit Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of clinical assets to address the unmet medical needs of patients, through exclusive relationships. Its medical needs in the areas of autoimmune disease and idiopathic male infertility. The company is headquartered in San Diego, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Nirland Ltd | 10% Owner | Oct 01 '24 | Sale | 0.11 | 1,250,000 | 141,375 | 10,233,177 | Oct 02 05:02 PM | Nirland Ltd | 10% Owner | Sep 30 '24 | Sale | 0.12 | 1,016,823 | 122,019 | 11,483,177 | Oct 02 05:02 PM | Nirland Ltd | 10% Owner | Oct 02 '24 | Sale | 0.10 | 333,177 | 34,251 | 9,900,000 | Oct 02 05:02 PM | Regan Andrew | Director | Jul 16 '24 | Sale | 0.32 | 10,244,392 | 3,246,448 | 1,691,727 | Sep 19 05:01 PM | Regan Andrew | Director | Jul 17 '24 | Sale | 0.26 | 1,514,100 | 391,092 | 177,627 | Sep 19 05:01 PM |
|
|
| |
|
Market Cap | 2.49B | EPS (ttm) | -3.81 |
P/E | - | EPS this Y | 4.32% |
Forward P/E | - | EPS next Y | 30.95% |
PEG | - | EPS past 5Y | -6.09% |
P/S | 8.43 | EPS next 5Y | - |
P/B | 5.06 | EPS Q/Q | -46.26% |
Dividend | - | Sales Q/Q | 27.81% |
Insider Own | 4.26% | Inst Own | 106.40% |
Insider Trans | -1.66% | Inst Trans | 2.41% |
Short Float | 15.94% | Earnings | Aug 02/b |
Analyst Recom | 1.83 | Target Price | 52.20 |
Avg Volume | 872.33K | 52W Range | 14.42 - 60.90 |
|
|
|
Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck on February 4, 2013 and is headquartered in San Francisco, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Green Paula | Officer | Oct 02 '24 | Proposed Sale | 43.21 | 3,310 | 143,027 | | Oct 02 05:01 PM | Cho Dennis | Officer | Oct 02 '24 | Proposed Sale | 43.21 | 3,104 | 134,126 | | Oct 02 04:44 PM | Leproust Emily M. | Officer | Oct 02 '24 | Proposed Sale | 43.21 | 13,605 | 587,880 | | Oct 02 04:36 PM | Finn Patrick John | Officer | Oct 02 '24 | Proposed Sale | 43.21 | 6,865 | 296,641 | | Oct 02 04:33 PM | Cho Dennis | See Remarks | Sep 20 '24 | Sale | 46.94 | 234 | 10,984 | 78,393 | Sep 24 04:05 PM |
|
|
|
|
Market Cap | 41.90B | EPS (ttm) | -1.16 |
P/E | - | EPS this Y | 7.35% |
Forward P/E | 40.23 | EPS next Y | 27.35% |
PEG | - | EPS past 5Y | 15.38% |
P/S | 9.61 | EPS next 5Y | 27.95% |
P/B | 40.65 | EPS Q/Q | -230.31% |
Dividend | - | Sales Q/Q | 20.50% |
Insider Own | 39.95% | Inst Own | 52.91% |
Insider Trans | -1.97% | Inst Trans | -4.54% |
Short Float | 1.87% | Earnings | Aug 01/a |
Analyst Recom | 1.96 | Target Price | 207.45 |
Avg Volume | 1.82M | 52W Range | 135.29 - 258.69 |
|
|
|
Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Cannon-Brookes Michael | CEO, Co-Founder | Oct 01 '24 | Sale | 159.81 | 7,948 | 1,270,159 | 500,724 | Oct 02 05:00 PM | Farquhar Scott | Director | Oct 01 '24 | Sale | 159.81 | 7,948 | 1,270,159 | 500,724 | Oct 02 05:00 PM | Cannon-Brookes Michael | CEO, Co-Founder | Sep 30 '24 | Sale | 159.47 | 7,948 | 1,267,429 | 0 | Oct 01 04:15 PM | Farquhar Scott | Director | Sep 30 '24 | Sale | 159.46 | 7,948 | 1,267,428 | 0 | Oct 01 04:14 PM | Cannon-Brookes Michael | CEO, Co-Founder | Sep 27 '24 | Sale | 161.30 | 7,948 | 1,281,996 | 7,948 | Sep 30 06:03 PM |
|
|
| |
|
Market Cap | 63.26B | EPS (ttm) | -1.12 |
P/E | - | EPS this Y | -3.15% |
Forward P/E | 29.07 | EPS next Y | 71.80% |
PEG | - | EPS past 5Y | -29.04% |
P/S | 11.98 | EPS next 5Y | 21.09% |
P/B | 4.45 | EPS Q/Q | 7.34% |
Dividend | 0.33% | Sales Q/Q | -5.07% |
Insider Own | 1.30% | Inst Own | 87.27% |
Insider Trans | -2.13% | Inst Trans | 0.47% |
Short Float | 2.22% | Earnings | Aug 29/a |
Analyst Recom | 1.21 | Target Price | 92.59 |
Avg Volume | 11.42M | 52W Range | 46.07 - 85.76 |
|
|
Sep-27-24 09:04AM
|
Marvell Technology, Inc. (MRVL) Surpasses Q2 Expectations Amid Growing AI Demand, Secures Price Target Boost
(Insider Monkey) |
08:15AM
|
History Says the S&P 500 Could Soar: 2 Monster Stocks to Buy, According to These Wall Street Analysts
(Motley Fool) |
Sep-26-24 08:24AM
|
Qualcomm, Broadcom, Marvell Stocks Rise. The AI Run Gets Boost After Microns Strong Outlook.
(Barrons.com) |
Sep-25-24 10:07AM
|
This Analysts AI Prediction About Marvell Technology (MRVL) Was Right Stock Up 36% Since His Comments
(Insider Monkey) |
Sep-24-24 04:26PM
|
AI Investments Not Slowing Down, Nvidia Stock Analyst Says
(Investor's Business Daily) |
Sep-20-24 09:00AM
|
Marvell to Showcase Optical Interconnect Innovations for Accelerated Infrastructure at ECOC 2024
(PR Newswire) |
08:48AM
|
Marvell (MRVL): Strong Industry, Solid Earnings Estimate Revisions
(Zacks) |
Sep-19-24 09:00AM
|
Is Trending Stock Marvell Technology, Inc. (MRVL) a Buy Now?
(Zacks) |
Sep-18-24 07:58AM
|
Is Marvell Technology, Inc. (MRVL) The Worst 5G Stock to Buy According to Short Sellers?
(Insider Monkey) |
Sep-17-24 01:17PM
|
Marvell Technology, Inc. (NASDAQ:MRVL): A Chip Stock Powering The AI Boom
(Insider Monkey) |
|
Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Casper Mark | EVP & Chief Legal Officer | Oct 01 '24 | Sale | 70.83 | 2,500 | 177,075 | 22,494 | Oct 02 04:59 PM | MARK CASPER | Officer | Oct 01 '24 | Proposed Sale | 72.12 | 2,500 | 180,300 | | Oct 01 04:29 PM | MURPHY MATTHEW J | Chairman of the Board and CEO | Sep 16 '24 | Sale | 73.29 | 6,000 | 439,740 | 208,915 | Sep 17 07:06 PM | Meintjes Willem A | Chief Financial Officer | Sep 16 '24 | Sale | 73.87 | 1,500 | 110,805 | 111,753 | Sep 17 06:49 PM | Tamer Ford | Director | Sep 15 '24 | Option Exercise | 0.00 | 4,354 | 0 | 49,327 | Sep 17 06:47 PM |
|
|
|
|
Market Cap | 6.48B | EPS (ttm) | -5.29 |
P/E | - | EPS this Y | 156.09% |
Forward P/E | 34.78 | EPS next Y | 138.09% |
PEG | - | EPS past 5Y | -2.82% |
P/S | 0.54 | EPS next 5Y | - |
P/B | - | EPS Q/Q | 16.17% |
Dividend | - | Sales Q/Q | -1.70% |
Insider Own | 27.92% | Inst Own | 89.55% |
Insider Trans | -0.55% | Inst Trans | -1.33% |
Short Float | 23.58% | Earnings | Aug 01/b |
Analyst Recom | 2.05 | Target Price | 62.93 |
Avg Volume | 4.33M | 52W Range | 38.02 - 76.18 |
|
|
|
Wayfair, Inc. engages in an online home furnishing store. It operates through the U.S. and International segments. The U.S. segment consists of amounts earned through product sales through the company's five distinct sites in the U.S. and through websites operated by third parties in the U.S. The International segment is composed of earnings through product sales in international sites. The company was founded by Steven K. Conine and Niraj S. Shah in May 2002 and is headquartered in Boston, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Tan Fiona | Officer | Oct 02 '24 | Proposed Sale | 53.06 | 10,040 | 532,759 | | Oct 02 04:58 PM | Gulliver Kate | Officer | Oct 02 '24 | Proposed Sale | 53.06 | 7,330 | 388,894 | | Oct 02 04:50 PM | Netzer Thomas | Officer | Oct 02 '24 | Proposed Sale | 53.06 | 8,435 | 447,556 | | Oct 02 04:42 PM | Blotner Jon | Officer | Oct 02 '24 | Proposed Sale | 52.39 | 6,055 | 317,226 | | Oct 02 04:25 PM | Netzer Thomas | Chief Operating Officer | Sep 17 '24 | Sale | 49.42 | 1,011 | 49,964 | 151,802 | Sep 18 06:24 PM |
|
|
| |
|
Market Cap | 104.83B | EPS (ttm) | 0.82 |
P/E | 102.91 | EPS this Y | -43.63% |
Forward P/E | 11.69 | EPS next Y | 90.08% |
PEG | 17.21 | EPS past 5Y | 1.55% |
P/S | 3.77 | EPS next 5Y | 5.98% |
P/B | 5.74 | EPS Q/Q | 55.31% |
Dividend | 3.65% | Sales Q/Q | 5.46% |
Insider Own | 0.21% | Inst Own | 84.91% |
Insider Trans | -2.59% | Inst Trans | 0.85% |
Short Float | 1.61% | Earnings | Aug 08/a |
Analyst Recom | 2.17 | Target Price | 84.59 |
Avg Volume | 6.55M | 52W Range | 62.07 - 87.86 |
|
|
|
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Parsey Merdad | Chief Medical Officer | Oct 01 '24 | Sale | 83.83 | 2,000 | 167,660 | 100,189 | Oct 02 04:58 PM | MERDAD V PARSEY | Officer | Oct 01 '24 | Proposed Sale | 83.83 | 2,000 | 167,660 | | Oct 01 04:27 PM | Parsey Merdad | Chief Medical Officer | Sep 12 '24 | Option Exercise | 57.92 | 25,000 | 1,448,000 | 123,435 | Sep 13 07:07 PM | Parsey Merdad | Chief Medical Officer | Sep 12 '24 | Sale | 84.50 | 21,246 | 1,795,287 | 102,189 | Sep 13 07:07 PM | Mercier Johanna | Chief Commercial Officer | Sep 12 '24 | Sale | 83.78 | 29,357 | 2,459,577 | 78,127 | Sep 13 05:08 PM |
|
|
|
|
Market Cap | 187.82B | EPS (ttm) | 7.71 |
P/E | 21.85 | EPS this Y | 19.25% |
Forward P/E | 15.10 | EPS next Y | 11.10% |
PEG | 1.73 | EPS past 5Y | - |
P/S | 5.03 | EPS next 5Y | 12.63% |
P/B | 7.63 | EPS Q/Q | 17.04% |
Dividend | 2.00% | Sales Q/Q | 11.15% |
Insider Own | 0.15% | Inst Own | 77.90% |
Insider Trans | -5.71% | Inst Trans | -0.30% |
Short Float | 2.14% | Earnings | Jul 31/a |
Analyst Recom | 1.97 | Target Price | 218.35 |
Avg Volume | 8.94M | 52W Range | 104.33 - 230.63 |
|
|
|
QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
THOMPSON JAMES H | Chief Technology Officer | Oct 01 '24 | Option Exercise | 0.00 | 9,575 | 0 | 222,939 | Oct 02 04:56 PM | THOMPSON JAMES H | Chief Technology Officer | Oct 01 '24 | Sale | 169.80 | 8,000 | 1,358,400 | 213,364 | Oct 02 04:56 PM | ROGERS ALEXANDER H | President QTL & Global Affairs | Oct 01 '24 | Option Exercise | 0.00 | 5,319 | 0 | 37,190 | Oct 02 04:55 PM | ROGERS ALEXANDER H | President QTL & Global Affairs | Oct 02 '24 | Sale | 166.15 | 3,245 | 539,157 | 32,231 | Oct 02 04:55 PM | Palkhiwala Akash J. | CFO & COO | Oct 01 '24 | Option Exercise | 0.00 | 5,107 | 0 | 56,544 | Oct 02 04:55 PM |
|
|
|
|
Market Cap | 2029.55B | EPS (ttm) | 6.97 |
P/E | 23.65 | EPS this Y | 31.76% |
Forward P/E | 19.01 | EPS next Y | 13.52% |
PEG | 1.15 | EPS past 5Y | 21.56% |
P/S | 6.19 | EPS next 5Y | 20.50% |
P/B | 6.75 | EPS Q/Q | 31.36% |
Dividend | 0.23% | Sales Q/Q | 13.46% |
Insider Own | 52.52% | Inst Own | 37.99% |
Insider Trans | -0.01% | Inst Trans | -0.22% |
Short Float | 1.36% | Earnings | Jul 23/a |
Analyst Recom | 1.58 | Target Price | 202.75 |
Avg Volume | 25.35M | 52W Range | 120.21 - 191.75 |
|
|
|
Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Pichai Sundar | Chief Executive Officer | Oct 02 '24 | Sale | 167.07 | 22,500 | 3,759,083 | 2,129,306 | Oct 02 04:56 PM | O'Toole Amie Thuener | VP, Chief Accounting Officer | Oct 01 '24 | Sale | 168.84 | 1,367 | 230,804 | 29,183 | Oct 02 04:31 PM | SUNDAR PICHAI | Director | Oct 02 '24 | Proposed Sale | 168.42 | 22,500 | 3,789,450 | | Oct 02 04:19 PM | PICHAI FAMILY FOUNDATION | Director | Oct 02 '24 | Proposed Sale | 168.42 | 4,000 | 673,680 | | Oct 02 04:18 PM | WALKER JOHN KENT | President, Global Affairs, CLO | Sep 27 '24 | Sale | 165.47 | 16,802 | 2,780,294 | 43,999 | Sep 30 06:36 PM |
|
|
|